McKesson Corporation vs Tesla, Inc. — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Tesla, Inc. trades at $379 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 13.6× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Tesla, Inc. for 88 Days on average.
| MCK | TSLA | |
|---|---|---|
Market Cap | $108.46B | $1.48T |
Volume | 712,607 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $489.88 |
52-Week Low | $725.17 | $298.16 |
Typical Hold Time | 74 Days | 88 Days |
Enterprise Value | $115.00B | $1.45T |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Tesla (TSLA) trades at $377.61, down 0.81% amid mixed signals. Technical analysis shows a bullish trend with key support at $375, while fundamentals reveal high valuation multiples (P/E 349.82) despite recent earnings beats. The company faces margin compression with net income declining to $3.79B in 2025. Recent news highlights regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and a potential cheaper EV model launch.
Tesla's investment case balances innovation leadership against valuation concerns. Upside potential exists from autonomous driving advances and energy/robotics growth, but risks include intense EV competition and execution challenges. Analysts maintain a cautious stance with 41% buy ratings and a $441.36 consensus target, suggesting modest upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →